TLR3 and familial pancreatic carcinoma: The FDA has granted the orphan drug designation to the TLR3 agonist poly(I:C)-expressing rabies virus-based vaccine YS-ON-001 for the treatment of hepatocellular carcinoma and pancreatic cancer [44].